» Authors » Piotr Pruszczyk

Piotr Pruszczyk

Explore the profile of Piotr Pruszczyk including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 295
Citations 5788
Followers 0
Related Specialties
Top 10 Co-Authors
Published In
Affiliations
Soon will be listed here.
Recent Articles
1.
Slawek-Szmyt S, Stepniewski J, Kurzyna M, Klaudel J, Kuliczkowski W, Lewandowski M, et al.
Respir Res . 2025 Mar; 26(1):87. PMID: 40045310
Background: Data on interventional treatment of intermediate-high (and high-risk pulmonary embolism (PE) are limited. The authors sought to evaluate the safety and efficacy of catheter-directed mechanical aspiration thrombectomy (CDMT) in...
2.
Kurnicka K, Perzanowska-Brzeszkiewicz K, Galecka-Nowak M, Cader T, Dzikowska-Diduch O, Ciurzynski M, et al.
Kardiol Pol . 2025 Feb; PMID: 39976497
No abstract available.
3.
Jermakow M, Machowski M, Galecka-Nowak M, Deutsch K, Il A, Imiela A, et al.
J Clin Med . 2025 Feb; 14(3). PMID: 39941354
The primary role of a pulmonary embolism response team (PERT) is to support decision-making processes regarding acute pulmonary embolism (PE) patients and provide advanced rescue therapies when needed. Despite a...
4.
Cader T, Karpeta E, Jankowski K, Lisik W, Pruszczyk P, Kurnicka K
Kardiol Pol . 2025 Jan; PMID: 39821622
No abstract available.
5.
Luijten D, van den Hout W, Boon G, Barco S, Bogaard H, Delcroix M, et al.
ERJ Open Res . 2025 Jan; 11(1. PMID: 39811556
Introduction: Achieving an early diagnosis of chronic thromboembolic pulmonary hypertension (CTEPH) in pulmonary embolism (PE) survivors results in better quality of life and survival. Importantly, dedicated follow-up strategies to achieve...
6.
Drozdz J, Morawiec R, Drozd M, Krzesinski P, Wozakowska-Kaplon B, Grabowski M, et al.
Kardiol Pol . 2025 Jan; PMID: 39743905
No abstract available.
7.
Dzikowska-Diduch O, Cader T, Jankowski K, Ou-Pokrzewinska A, Sznajder M, Siwiec J, et al.
J Clin Med . 2024 Nov; 13(22). PMID: 39598134
: The prevalence of portopulmonary hypertension (PoPH) is relatively low; however, its presence significantly worsens patients' prognosis. When diagnosed, PoPH can be effectively treated, and specific therapies can lead to...
8.
Waligora M, Kurzyna M, Mularek-Kubzdela T, Skoczylas I, Chrzanowski L, Blaszczak P, et al.
Chest . 2024 Nov; PMID: 39528108
Background: Current guidelines do not recommend β-blockers in pulmonary arterial hypertension (PAH) unless indicated by comorbidities. However, the evidence regarding the role of β-blockers in PAH is contradictory. Research Question:...
9.
Skonieczny G, Skowronska M, Dolacinska A, Ratajczak B, Sulik P, Doroba O, et al.
Cardiol J . 2024 Nov; 32(1):1-8. PMID: 39506902
Background: SARS-CoV-2 infection may lead to myocardial and endothelial damage. The present study sought to characterize the cardiovascular sequel in a large group of consecutive patients admitted for out-patient cardiovascular...
10.
Imiela A, Mikolajczyk T, Pruszczyk P
Arch Immunol Ther Exp (Warsz) . 2024 Oct; 72(1). PMID: 39466143
Accumulating data have shown a pathophysiological association between inflammatory pathways and thrombosis. Venous thromboembolism (VTE), which includes deep vein thrombosis (DVT) and acute pulmonary embolism (APE), is a significant health...